Matrix metalloproteinase 1 G/2 G gene polymorphism is associated with acquired atrioventricular block via linking a higher serum protein level

Jan-Yow Chen1,2,3, Kuan-Cheng Chang1,3 & Ying-Ming Liou2,4✉

Limited studies are available regarding the pathophysiological mechanism of acquired atrioventricular block (AVB). Matrix metalloproteinases (MMPs) and angiotensin-converting enzyme (ACE) have been implicated in the pathogenesis of arrhythmia. However, the relationship between these molecules and acquired AVB is still unclear. One hundred and two patients with documented acquired AVB and 100 controls were studied. Gene polymorphisms of the MMP1 and ACE encoding genes were screened by the gene sequencing method or polymerase chain reaction-fragment length polymorphism assay, followed by an association study. The frequencies of the MMP1 −1607 2G2G genotype and MMP1 −1607 2 G allele were significantly higher in the AVB group than that in the controls (OR = 1.933, P = 0.027 and OR = 1.684, P = 0.012, respectively). Consistently, the level of serum MMP1 was significantly greater in acquired AVB patients than that in controls (6568.9 ± 5748.6 pg/ml vs. 4730.5 ± 3377.1 pg/ml, P = 0.019). In addition, the MMP1 2G2G genotype showed a higher MMP-1 serum level than the other genotypes (1G1G/1G2G) (7048.1 ± 5683.0 pg/ml vs. 5072.4 ± 4267.6 pg/ml, P = 0.042). MMP1 1 G/2 G gene polymorphism may contribute to determining the disease susceptibility of acquired AVB by linking the MMP serum protein level.

Atrioventricular block (AVB) is a group of abnormal AV conduction disorders caused by a delay or interruption in the impulse connection from the atria to the ventricles due to structural or functional impairment1,2. AVB is one of the major disorders for patients requiring pacemaker implantation1,2. In an AV block condition, the wavelets cannot reach the ventricles or are delayed through the AV node, slowing down the heart beat and causing a serious condition1–3. The main causes of acquired AVB include idiopathic fibrosis, aging process in cardiomyocytes, degeneration, ischemia, infarction, infiltration disease or drugs1–4. Progressive idiopathic fibrosis related to an aging process of the cardiac skeleton is the most common cause of chronic acquired AVB2,4–8. It is generally accepted that familial and inherited AVB are caused by gene mutations and dysfunction of the conduction system during heart development9–12. In contrast, the pathophysiological mechanism of acquired AVB is currently unclear.

Matrix metalloproteinases (MMPs) and renin-angiotensin system (RAS) acting agents, including the angiotensin-converting enzyme (ACE) and angiotensinogen, have been reported to promote tissue fibrosis and the aging process13–15. MMPs and extracellular matrix (ECM) have been shown to control cardiac conduction and have been linked to the modification of gap junction proteins for atrioventricular conduction15,16. Although the aging process and progressive fibrosis have been thought to be the key events for age-related conduction disturbances, ECM alteration was shown to cause impulse-conduction disorders15–17. Studies have shown that MMPs and RAS acting agents are involved in the pathogenesis of arrhythmia and cardiac conduction18–22. Studies

1Division of Cardiovascular Medicine, Department of Medicine, China Medical University, Taichung, Taiwan.
2Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
3School of Medicine, China Medical University, Taichung, Taiwan.
4The iEGG and Animal Biotechnology Center, and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan. ✉e-mail: ymlion@dragon.nchu.edu.tw
in humans and animals demonstrated that modulation of MMP and RAS gene expression could lead to atrial fibrillation\textsuperscript{18,19}, non-familial sick sinus syndrome\textsuperscript{21}, and affect cardiac conduction after myocardial infarction\textsuperscript{17}, apoptosis of the conductive system\textsuperscript{22} and occurrence of ventricular arrhythmia\textsuperscript{23}. Here, we examined whether the polymorphisms of the genes encoding the MMPs and ACE could alter the disease susceptibility for acquired AVB by investigating the relationship between MMPs and ACE gene polymorphisms and disease susceptibility of acquired AVB. The results obtained indicated that MMP1 1 G/2 G gene polymorphism is associated with AVB via linking a higher serum protein level.

**Methods**

**Study population.** During the period from Sep 1, 2018 to Aug 31, 2019, a total of 102 patients with documented acquired AVB were enrolled as the patient group, and another 100 age and sex frequency-matched healthy individuals were enrolled as a control group (Table 1). The AVB was recorded and diagnosed with evidence of AV block by a series of electrocardiograms (ECG) and ambulatory ECG according to the international standard guidelines\textsuperscript{24}. The criteria for inclusion were symptomatic second and third degree AVB, which met evidence of AV block by a series of electrocardiograms (ECG) and ambulatory ECG according to the international standard guidelines\textsuperscript{24}. The results obtained indicated that MMP1 1 G/2 G gene polymorphism is associated with AVB via linking a higher serum protein level.

**Genomic study**

**Polymerase chain reaction.** Blood samples from patients were prepared, and genomic DNA was isolated using a DNA extraction kit (ILLUSTRA, GE HEALTHCARE). Polymerase chain reaction (PCR) was performed with 100 ng genomic DNA, 2–6 pmol of selected primers, 1X TAG polymerase buffer, and 0.25 units of AMPLITAG GOLD polymerase (THERMO FISHER) in a final reaction volume of 50 μL using a programmable thermal cycler (GENEAMP PCR System 2700, APPLIED BIOSYSTEMS, CA). The polymorphisms for MMP genes selected for screening included MMP1–1607 1 G/2 G (rs1799750), while the polymorphisms for ACE genes selected included ACE insertion/deletion (I/D) polymorphism.

**Genotyping.** The genotype analysis of the subjects was studied by electrophoresis, polymerase chain reaction–fragment length polymorphism assay or direct gene sequencing if appropriate. Genotyping for the ACE I/D polymorphisms was studied by electrophoresis, polymerase chain reaction–fragment length polymorphism assay. The primers for the ACE I/D gene polymorphisms were 5'-TGGAGGACCATCCATCCTTTTCT-3' (forward) and 5'-CAGGTCTTCATATTTCCGATGTGG-3' (reverse). Two fragments with different PCR product lengths were presented for the different genotypes (ACE I or ACE D genotypes). Electrophoresis was performed for genotyping. Thereafter, 10 μL of the products were loaded into a 3% agarose gel with ethidium bromide staining and separated by electrophoresis. Electrophoresis of the amplified products allowed to identify a 495-base pair fragment (insertion) and a 208-base pair fragment (deletion), respectively, on the gel for genotyping the ACE I/D polymorphisms. The gene polymorphisms were categorized as homozygotes (insertion type, II, as on lanes 1 and 3), heterozygotes (deletion type, ID, as on lanes 2 and 4), and heterozygotes (DD, as on lanes 5 and 6) as shown in Fig. \textsuperscript{1}. Genotyping for part of the PCR products was performed by gene sequencing for MMP1 gene polymorphisms. The primers for MMP1–320 T/C, 422 T/A and 519 A/G gene polymorphisms were

|                      | AVB (N = 102) | Control (N = 100) | P       |
|----------------------|---------------|-------------------|---------|
| Age (years)          | 69.9 ± 14.8   | 69.6 ± 8.8        | 0.869*  |
| Gender (male/female) | 40/62         | 37/63             | 0.773   |
| BMI (kg/m\(^2\))    | 24.5 ± 3.7    | 25.1 ± 3.1        | 0.196   |
| HT (n, %)            | 45 (44.1%)    | 47 (47.0%)        | 0.681   |
| DM (n, %)            | 24 (23.5%)    | 20 (20.0%)        | 0.543   |
| CAD (n, %)           | 9 (8.8%)      | 13 (13.0%)        | 0.341   |
| AF (n, %)            | 6 (5.9%)      | 5 (5.0%)          | 0.782   |

Table 1. General characteristics of patients included in the present study. *T-test; \(*2^\text{ chi-square test; AVB, atrioventricular block; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; AF, atrial fibrillation.*
were subsequently determined by gene sequencing using a genetic analyzer (ABI 3730 XL DNA Analyzer, APPLIED BIOSYSTEMS).

**Association study.** An association study between gene polymorphisms and AVB was performed to measure and compare the genotype distribution and allele frequency of the candidate genes in AV block and control groups.

**Measurement of serum MMP concentrations.** Serum samples were randomly obtained from 75 acquired AV block patients and 74 control individuals. The samples were stored at $-20^\circ\text{C}$ until the assays were performed. The serum MMP levels were detected using the enzyme-linked immunosorbent assay kit (ELISA) (INVITROGEN, CA, USA). The optical density (OD) was measured by an ELISA microplate reader. The concentration of MMP was determined from a standard curve according to the manufacturer’s instructions.

**Statistical analysis.** Student’s t test was used when continuous data were collected. Categorical data were compared by the conventional chi-square test if the observation numbers in all categories were larger than 5; otherwise, the Fisher exact test was used. The genotype proportions for Hardy–Weinberg equilibrium (HWE) were assessed for each gene polymorphism by using the conventional goodness-of-fit test. Haplotype analysis for the gene polymorphisms was estimated by using HAPLOVIEW software. Owing to the short distances between each polymorphism location on the MMP1 gene, gene polymorphisms may not separate by recombination and were in linkage disequilibrium (LD). Therefore, pairwise measurement of LD was performed to test the LD between the MMP1 gene polymorphisms. LD was estimated by $D'$ and $r^2$. We also selected the $r^2$ value to confirm LD because the magnitude of $D'$ significantly depends on the sample size. Expectation-maximization (EM)-based haplotype frequency estimation was performed to determine whether any specific haplotypes were associated with acquired AVB on the basis of previous reports. The statistical significance of LD was defined as $r^2 > 1/3$ and $D' > 0.7$, as suggested by previous reports. A P value $< 0.05$ was considered statistically significant.

**Results**

**Patient characteristics.** The clinical features of AVB patients and controls are summarized in Table 1. Those patients with a history of familial AVB, severe systemic disease, acute coronary syndrome, drug-induced AVB, or AVB with reversible cause were excluded. The baseline clinical characteristics, including age, gender, percentage of patients with hypertension, diabetes mellitus (DM), coronary artery disease (CAD) and atrial fibrillation (AF), were similar between the 2 groups.

**HWE and LD measurements.** Five polymorphic sites at positions $-320$, $-340$, $-422$, $-519$ and $-1607$ were found within the promoter region of the MMP-1 gene. The HWE for genotype distributions was assessed for each MMP1 promoter polymorphism at the $-320$, $-340$, $-422$, $-519$ and $-1607$ positions for the AVB and control groups by the conventional chi-square goodness-of-fit test. The MMP1 genotype distribution in the AVB patients and controls did not significantly deviate from the HWE for the AVB patients (P-values were 0.724, 0.5952, 0.1116, 0.5434 and 0.1621, respectively) and control groups (P-values were 0.934, 0.838, 0.08, 1.0 and 0.2327, respectively). The pairwise linkage among these five polymorphic sites on the MMP1 promoter gene was evaluated by the LD test using $D'$ and $r^2$. The $D'$ values of the loci pairs for $-320/-340$, $-320/-422$, $-320/-519$, $-320/-1607$, $-340/-422$, $-340/-519$, $-340/-1607$, $-422/-519$, $-422/-1607$ and $-519/-1607$ were 0.129, 0.137, 0.536, 0.265, 0.054, 0.758, 0.116, 1.0, 0.215, and 0.743, respectively. The corresponding values for $r^2$ were 0.004, 0.012, 0.036, 0.031, 0.0, 0.009, 0.004, 0.045, 0.013, 0.085, respectively (Fig. 2). The $D'$ values indicated a significant linkage in the loci pairs of $-340/-519$ and $-519/-1607$. However, the $r^2$ values for these three loci pairs were low and indicated no significant linkage in the loci pairs. This inconsistent result between the $D'$ and $r^2$ measurements is likely due to the small sample size and the genetic diversity within the population.
r² values may be due to the relatively small sample size in this study. The high D' values and the low r² values of these 2 loci pairs (−340/−519, −159/−1607) indicate an incomplete linkage among these 2 loci pairs, which explains the wide distribution of haplotypes for the MMP-1 gene.

ACE I/D gene polymorphisms were found for the ACE gene. The ACE I/D genotype distribution in AVB patients and the control group did not significantly deviate from HWE (P = 0.32 and 0.70, respectively).

Single locus gene association analysis for MMP-1 gene polymorphisms and AVB. Five MMP1 gene polymorphisms (−1607 1 G/2 G, −519 A/G, −422 A/T, −340 C/T and −320 C/T) and one ACE gene polymorphism (I/D) were identified in our study. In addition, an association study showed that the ACE I/D polymorphisms were not associated with acquired AVB. A significant difference was noted in the distribution of the genotypes of MMP1 −1607 1 G/2 G polymorphisms between AVB and control subjects (P = 0.027). The 2G-dominant genotype (2G2G/1 G2G) frequency of the −1607 1 G/2 G polymorphism was significantly higher in acquired AVB patients than that in controls (OR = 2.59, 95% CI 1.014–6.587, P = 0.047). The 2G2G genotype frequency of the −1607 1 G/2 G polymorphism was significantly higher in the AVB group than that in the control group (45/102 vs. 29/100, OR = 1.933, 95% CI 1.079–3.461, P = 0.027). The 2G allele frequency of −1607 1 G/2 G was significantly higher in the AVB group than that in the control group (140/204 vs. 113/200, OR = 1.684, CI 1.121–2.530, P = 0.012) (Table 2). The results of the single locus analysis indicated that the MMP1 −1607 1 G/2 G gene polymorphism is associated with the disease susceptibility of acquired AVB.

Association between the MMP1 promoter haplotypes and AVB. Seven major haplotypes in the MMP-1 promoter showing a haplotype frequency higher than 0.05 were identified in the present study, and their relationship with AVB was examined (Table 3). The 2G-A-T-T-T (−1607, −519, −420, −340, −320) haplotype demonstrated a significantly higher frequency in the AVB group than the control group (haplotype frequency: 0.1617 vs. 0.0875; OR = 2.01, P = 0.0239; Table 3). The results of the haplotype analysis showed a significant association between the MMP1 −1607 1 G/2 G gene polymorphism and AVB.

Serum MMP1 protein levels in the various MMP1 polymorphisms. The MMP1 serum protein level was significantly higher in the AV block group than in the control group (6568.9 ± 5748.6 pg/ml vs. 4730.5 ± 3377.1 pg/ml, P = 0.019). In addition, the 2G2G genotype showed a greater MMP-1 serum level than the 1G2G and 1G1G genotypes (7048.1 ± 5683.0 pg/ml vs. 5072.4 ± 4267.6 pg/ml, P = 0.042) (Fig. 3).

Discussion
Increasing evidence suggests that gene mutations and dysfunction of the conduction system during heart development may result in familial AVB. However, only a few data are available regarding the pathophysiology of acquired AVB. Idiopathic fibrosis is the most common cause of acquired AV block. Since the possible pathogenesis of acquired AVB is quite different from familial AVB, it is of interest to explore the underlying mechanism of acquired AVB. In the present study, we found that the MMP1 1 G/2 G gene polymorphism is highly associated with acquired AVB via linking a higher serum MMP-1 level. The results of the present study may provide crucial and useful information for the prevention of acquired AVB.

Single locus, haplotype analyses and serum level measurement of MMP1 gene polymorphisms. In a single locus analysis study, the results showed that the frequency of the MMP1 −1607 2G2G...
The 2G-dominant (2G2G/2G1G) genotype frequency of the MMP-1 \(-1607\) 1G/2G gene polymorphism was also significantly higher in the AV block group than in the controls. In the haplotype analysis, we found 7 major haplotypes of the MMP1 promoter polymorphism in the studied population (Table 3). The 2G-A-T-T-T haplotype was associated with a significant risk for AV block in comparison to the controls. These results suggested that the \(-1607\) 1G/2G polymorphism is a locus significantly associated with acquired AV block.

Consistently, the MMP1 serum protein level was significantly higher in the 2G2G genotypes than that in the other genotypes in the study population. The serum MMP1 protein levels were also higher in AVB patients than in the controls. These data suggested that MMP1 1G/2G gene polymorphism is associated with disease.

Table 2. Distribution of genotypes and alleles of MMP1 and ACE in patients with and without AV block. AVB, atrioventricular block. P values obtained based on \(\chi^2\) test or Fisher's exact test; the upper P value is for comparison of genotype frequencies, and the lower is for allele frequencies.

| Gene polymorphism | Genotypes and Alleles | AVB patients (N = 102) | Control patients (N = 100) | P        |
|-------------------|-----------------------|------------------------|---------------------------|----------|
| MMP-1 gene        |                       |                        |                           |          |
| \(-1607\) (1G/2G) | 1G1G – n (%)          | 7 (6.9)                | 16 (16.0)                 |          |
|                   | 1G2G – n (%)          | 50 (49.0)              | 55 (55.0)                 |          |
|                   | 2G2G – n (%)          | 45 (44.1)              | 29 (29.0)                 | 0.027    |
|                   | 2G2G/1G2G + 1G1G – n (%) | 45 (44.1):57 (55.9) 29 | 29 (29.0):71 (71.0) | 0.027    |
|                   | 1G2G + 2G2G/1G1G – n (%) | 95 (93.1):7 (6.9)     | 84 (84.0):16 (19.0)      | 0.047    |
|                   | 1G2G – n (%)          | 64 (31.4):140 (68.6)  | 87 (43.5):113 (56.5)     | 0.012    |
| \(-519\) (A/G)    | AA – n (%)            | 88 (86.3)              | 81 (81.0)                 |          |
|                   | AG – n (%)            | 14 (13.7)              | 18 (18.0)                 |          |
|                   | GG – n (%)            | 0 (0)                  | 1 (1.0)                   | 0.389    |
|                   | A:A – n (%)           | 190(94.1):14 (6.9)     | 180 (90.0):20 (10.0)     | 0.256    |
| \(-422\) (A/T)    | AA – n (%)            | 47 (46.1)              | 52 (52.0)                 |          |
|                   | AT – n (%)            | 39 (38.5)              | 35 (35.0)                 |          |
|                   | TT – n (%)            | 16 (15.7)              | 13 (13.0)                 | 0.692    |
| \(-340\) (T/C)    | TT – n (%)            | 79 (77.5)              | 70 (70.0)                 |          |
|                   | TC – n (%)            | 22 (21.6)              | 27 (27.0)                 |          |
|                   | CC – n (%)            | 1 (1.0)                | 3 (3.0)                   | 0.357    |
|                   | T:C – n (%)           | 180 (88.2):2 (11.8)    | 167 (83.5):33 (16.5)     | 0.172    |
| \(-320\) (T/C)    | TT – n (%)            | 19 (18.6)              | 17 (17.0)                 |          |
|                   | TC – n (%)            | 52 (51.0)              | 48 (48.0)                 |          |
|                   | TT – n (%)            | 31 (30.4)              | 35 (35.0)                 | 0.803    |
| ACE gene          |                       |                        |                           |          |
| 1/D               | II – n (%)            | 51 (50)                | 46 (46.0)                 |          |
|                   | ID – n (%)            | 40 (39.2)              | 45 (45.0)                 |          |
|                   | DD – n (%)            | 11 (10.8)              | 9 (9.0)                   | 0.693    |
|                   | DD – n (%)            | 142 (69.6):62 (30.4)   | 137 (68.5):63 (31.5)     | 0.81     |

Table 3. Haplotype frequency estimates of the MMP-1 gene in patients with atrioventricular block and controls. Haplotypes are not listed if all the estimated frequencies are <0.05 in patients with AVB, controls, and overall population.

| Haplotype | Overall | AVB | Controls | OR | P  |
|-----------|---------|-----|----------|----|----|
| \(-1607\) |         |     |          |    |    |
| [519-420] |         |     |          |    |    |
| 340-320   |         |     |          |    |    |
| 2G A A T C | 0.221   | 0.2294 (46.8:157.2) | 0.2130 (42.6:157.4) | 1.10 | 0.6904 |
| 1G A A T C | 0.157   | 0.1392 (28.4:175.6) | 0.1745 (34.9:165.1) | 0.76 | 0.3269 |
| 2G A T T T | 0.125   | 0.1617 (33.0:177.0) | 0.0875 (17.5:182.5) | 2.01 | 0.0239 |
| 2G A A T T | 0.123   | 0.1363 (27.8:176.2) | 0.1100 (22.0:178.0) | 1.28 | 0.4160 |
| 1G A T T C | 0.067   | 0.0578 (11.8:192.2) | 0.0760 (15.2:184.8) | 0.75 | 0.4728 |
| 2G A T T C | 0.064   | 0.0784 (16.0:188.0) | 0.0495 (9.9:190.1)  | 1.63 | 0.2358 |
| 1G G A T T | 0.054   | 0.0475 (9.7:194.3)  | 0.0595 (11.9:188.1) | 0.79 | 0.5897 |
susceptibility for acquired AVB via linking a higher serum MMP1 protein level. Taken together, the results implicated that gene polymorphisms of MMP molecules are associated with the disease susceptibility of acquired AVB via linking the MMP1 serum protein levels.

**The role of MMP in tissue fibrosis and cardiac conduction.** AVB has been reported to be closely related to fibrosis over the conduction system\(^5^,\(^6^\). Tissue fibrosis is associated with MMP molecule expression, the renin-angiotensin system and TGF beta\(^13^–\(^15^\). Studies using transgenic mice demonstrated that the overexpression of the angiotensin II type I (AT1) receptor in the myocardium is associated with AVB\(^30^\). In a post MI rat model, downregulation of MMP has been demonstrated to protect disturbance in cardiac conduction\(^31^\). A study of MMP deletion in a transgenic mouse model showed that MMP deletion decreased gap junction protein degradation and recovered cardiac conduction velocity in post-myocardial infarction mice\(^17^\). Apparently, MMP plays an important role in the modification of cardiac conduction.

**The possible pathophysiology of MMP1 1 G/2 G gene polymorphisms affecting serum protein levels.** The 1 G/2 G polymorphism has been reported to affect an Ets binding site and increase MMP1 gene transcription\(^32^,\(^33^\). Consistently, a close association was found between the −1607 1 G/2 G polymorphism and MMP1 serum levels\(^34^\). The MMP1 −1607 2 G allele, but not the 1 G allele, accounted for the increased levels of pre-mRNA and protein. In addition, variation in MMP1 haplotypes has been reported to affect serum MMP-1 level\(^34^,\(^35^\). A study of the secondary structures of pre-mRNA of the MMP1 −1607 1 G/2 G gene polymorphism has shown that the pre-mRNA secondary structure of the 2 G allele is more stable than the 1 G structure based on deduction of the minimum free energy\(^34^\). The lower free energy and more stable pre-mRNA structure of the 2 G allele may cause the increased expression of the 2 G/2 G gene polymorphism with higher serum protein levels and therefore increased the risk of acquired AV block\(^34^\).

**Meta-analysis of genetic association study in diseases.** A single case-control genetic study is of limited to reveal the true association between the genotypes and the disease susceptibility. Alternatively, meta-analysis is a useful statistical approach method to analyze the divergence among several independent studies by interrogating available data published. In addition, meta-analysis of genetic association study provide a better power to derive a more precise relationship between gene polymorphisms and disease susceptibility\(^36^–\(^38^\). Currently, most of meta-analyses of genetic association studies are usually conducted by comparing genotype frequencies between cases and controls under various genetic models. A study with meta-analysis of genetic association has been conducted to show the relationship between MMP gene polymorphisms and lung cancer by logistic regression analysis\(^36^\). In addition, meta-analysis has also been used to investigate the relationship of steroid medication and outcome of congenital conduction disorder\(^38^\). However, no meta-analysis of genetic association study has been reported for the relationship between acquired AVB and MMP gene polymorphisms. To our best knowledge, the present study is the first case-control genetic association study to demonstrate that there is a close association between MMP1 gene polymorphisms and acquired AVB and provide functional results to clarify the underlying mechanism of acquired AVB. Our results may provide biological insights for acquired AVB. Thus far no other case-control genetic association study is available for resolving the relationship between MMP1 gene polymorphisms and the acquired AVB. The future study with a well-designed meta-analysis is needed to reconfirm the role of MMP gene polymorphisms in the disease susceptibility to acquired AVB.

![Figure 3. Serum MMP1 protein levels. (A) The serum MMP1 protein level in the AVB patients was significantly greater than that in the controls. (B) The serum MMP1 protein level of the studied subjects with a 2G2G genotype is significantly higher than that in subjects with non-2G2G genotypes in the present study. *p<0.05.](image-url)
Study limitations. In the present study, we provided evidence obtained with the gene association study and with the functional measurement of serum MMP1 protein levels to support the crucial role of MMP1 gene polymorphism in the pathophysiology of acquired AVB. However, the direct impact of MMP1 gene polymorphism on cardiac cells located at the AV node still warrants further study. Another limitation is that the population of the present study is relatively small, and it needs to be further confirmed by large-scale studies.

Conclusions

Patients with acquired AVB have a higher frequency of the 2 G allele and a higher distribution of 2G2G genotype or 2G-dominant genotypes for the MMP1 1G/2G polymorphism. Consistently, the MMP1 protein serum level was significantly higher in the 2G2G genotypes than in the other genotypes in the study population. Taken together, these results suggest that the MMP1 1G/2G polymorphism is associated with the disease susceptibility of acquired AVB via linking higher serum MMP1 protein levels. Here, we provide the potential mechanism for the acquired AV block, which might be useful for disease prevention.

Received: 21 February 2020; Accepted: 29 May 2020; Published online: 18 June 2020

References

1. Manzur, J. M. & DiMarco, J. P. Evaluation and Management of bradyarrhythmia. N. Engl. J. Med. 342, 703–709, https://doi.org/10.1056/NEJM200003093421006 (2000).
2. Vogler, J., Breithardt, G. & Eckardt, L. Bradyarrhythmias and conduction blocks. Rev. Esp. Cardiol. 65, 656–667, https://doi.org/10.1016/j.rec.2012.01.025 (2012).
3. Mirza, M., Strunets, A., Shen, W. K. & Jahangir, A. Mechanisms of arrhythmias and conduction disorders in older adults. Clin. Geriatr. Med. 28, 555–573, https://doi.org/10.1016/j.cger.2012.08.005 (2012).
4. Grebe, G. C., Voemel, C., Kurtz, R. K. & Vester, E. G. Correlation of electrocardiographic conduction abnormalities with myocardial fibrosis and scar in late enhancement. J. Cardiovasc. Magn. Reson. 17, P189, https://doi.org/10.1186/1532-4429-17-S1-P189 (2015).
5. Lev, M. Anatomic basis for atrioventricular block. Am J Med. 74, 742–748, https://doi.org/10.1016/0002-9343(64)90022-1 (1964).
6. Davies, M. & Harris, A. Pathological basis of primary heart block. Br. Heart J. 31, 219–226, https://doi.org/10.1136/hrt.31.3.219 (1969).
7. Teragaki, M. et al. Endomyocardial biopsy findings in patients with atrioventricular block in the absence of apparent heart disease. Heart Vessel. 14, 170–176, https://doi.org/10.1007/BF02483003 (1999).
8. Waller, B. F., Gering, L. E., Branayas, N. A. & Slack, J. D. Anatomy, histology, and pathology of the cardiac conduction system—Part V. Circ. Cardiol. 16, 565–569, https://doi.org/10.1002/clc.4960160710 (1993).
9. Liu, G. Y. Z. & Chen, W. Novel missense variant in TTN cosegregating with familial atrioventricular block. Eur. J. Med. Genet. 63, H103752, https://doi.org/10.1016/j.ejmg.2019.103752 (2019).
10. Asatryan, B. & Medeiros-Domingo, A. Molecular and genetic insights into progressive cardiac conduction disease. Europace 21, 1145–1158, https://doi.org/10.1093/europace/euz109 (2019).
11. Stallmeyer, B. et al. A mutation in the G-protein gene GNB2 causes familial sinus node and atrioventricular conduction dysfunction. Circ. Res. 120, e33–e44, https://doi.org/10.1161/circresaha.116.310112 (2017).
12. Thongnak, C. et al. Exome sequencing identifies compound heterozygous mutations in SCN5A associated with congenital complete heart block in the Thai population. Dis Markers. 3684965, https://doi.org/10.1155/2016/3684965 (2016).
13. Cortez, D. M. et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am. J. Physiol. Heart Circ. Physiol. 293, H3356–H3365, https://doi.org/10.1152/ajpheart.00928.2007 (2007).
14. Fan, D. T. A., Lee, J. & Kassiri, Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 5, 15, https://doi.org/10.1093/10.1093/ftr/eur011 (2012).
15. Rosenkranz, R. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63, 423–432, https://doi.org/10.1016/j.cardiores.2004.04.030 (2004).
16. Spadaccio, C. et al. The role of extracellular matrix in age-related conduction disorders: a forgotten player? J. Geriatr. Cardiol. 12, 26–42, https://doi.org/10.11909/jissn.1671-5411.2015.01015.025 (2015).
17. Lindsey, M. L. et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 113, 2919–2928, https://doi.org/10.1161/circulationaha.106.612960 (2006).
18. Nguyen, T. P., Zhihlin, Q. & Weiss, J. N. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J. Mol. Cell Cardiol. 70, 83–91, https://doi.org/10.1016/j.yjmcc.2013.10.018 (2014).
19. Lombardi, F., Belletti, S., Battezzati, P. M., Paccorla, R. & Biondi, M. L. MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation. J. Cardiovasc. Med. 12, 37–42, https://doi.org/10.1023/A:101549/CJM.0000013283403366 (2011).
20. Nakano, Y. et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J. Am. Coll. Cardiol. 43, 818–825, https://doi.org/10.1016/j.jacc.2003.08.060 (2004).
21. Chen, J. Y., Liao, Y., Wu, H. D. L., Lin, K. H. & Chang, K. C. Promoter polymorphism G-6A, which modulates angiotensinogen gene expression, is associated with non-familial sick sinus syndrome. PLoS One, e29951, https://doi.org/10.1371/journal.pone.0029951 (2012).
22. Yongvatcharanorn, U. et al. Angiotensin II may mediate apoptosis via AT1-receptors in the rat cardiac conduction system. J. Renin Angiotensin Aldosterone Syst. 5, 135–140, https://doi.org/10.3317/jraas.2004.0300 (2004).
23. Weng, C. H. et al. Pleiotropic effects of myocardial MMP-9 inhibition to prevent ventricular arrhythmia. Sci. Rep. 6, 38894, https://doi.org/10.1038/srep38894 (2016).
24. Kusumoto, F. M. et al. 2018 ACC/AHA/HRSA guideline on the evaluation and management of patients with bradyarrhythmia and cardiac conduction delay. Circulation 74, e51–e156, https://doi.org/10.1016/j.circrec.2018.10.043 (2019).
25. Vandenbroucke, J. P. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 4, e297, https://doi.org/10.1371/journal.pmed.004297 (2007).
26. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265, https://doi.org/10.1093/bioinformatics/bth457 (2005).
27. Dey, S. et al. Matrix metalloproteinase-1 (MMP-1) promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One 9, e88040, https://doi.org/10.1371/journal.pone.0088040 (2014).
28. Ardlie, K. G., Kruglyak, L. & Seielstad, M. Patterns of linkage disequilibrium in the human genome. Nat. Rev. Genet. 3, 299–309, https://doi.org/10.1038/nrg777 (2002).
29. Gabriel, S. B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225–2229, https://doi.org/10.1126/science.1069424 (2002).
30. Hein, L. et al. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc. Natl Acad. Sci. USA 94, 6391–6396, https://doi.org/10.1073/pnas.94.12.6391 (1997).
31. Yang, G. et al. Neuregulin-1 protects cardiac electrical conduction through downregulating matrix metalloprotease-9 and upregulating connexin 43 in a rat myocardial infarction model. Pharmacol 74, 231–234, https://doi.org/10.1691/ph.2019.8941 (2019).
32. Rutter, I. et al. A single nucleotide polymorphism in the matrix metalloprotease-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58, 5321–5325, https://cancerres.aacrjournals.org/content/58/23/5321.long (1998).
33. Affara, M. et al. MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics 12, 43, https://doi.org/10.1186/1471-2164-12-43 (2011).
34. Kondapalli, M. S. et al. MMP1 circulating levels and promoter polymorphism in risk prediction of coronary artery disease in asymptomatic first degree relatives. Gene 595, 115–120, https://doi.org/10.1016/j.gene.2016.09.043 (2016).
35. Abd-Allah, S. H., Shalaby, S. M., Pasha, H. F., El-Shal, A. S. & Abou El-Saoud, A. M. Variation of matrix metalloprotease 1 and 3 haplotypes and their serum levels in patients with rheumatoid arthritis and osteoarthritis. Genet. Test. Mol. Biomarkers 16, 15–20, https://doi.org/10.1089/gtmb.2011.0003 (2012).
36. Li, H., Liang, X., Qin, X., Cai, S. & Yu, S. Association of matrix metalloproteinase family gene polymorphisms with lung cancer risk: logistic regression and generalized odds of published data. Sci. Rep. 5, 10056, https://doi.org/10.1038/srep10056 (2015).
37. Zhang, J., Zhao, T., Xu, C. & Yu, H. Four polymorphisms in the IL-22 gene and the risk of cancer: A meta-analysis. J. Evid. Based Med. 11, 101–104, https://doi.org/10.1111/jebm.12296 (2018).
38. Ciardulli, A. et al. Maternal steroid therapy for fetuses with second-degree immune-mediated congenital atrioventricular block: a systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 97, 787–794, https://doi.org/10.1111/aogs.13338 (2018).

Acknowledgements
We are grateful to the staffs of our electrophysiology laboratory for their support to this study. This study was partly supported by funding from China Medical University Hospital in Taiwan (DMR-107-015).

Author contributions
J.Y.C. and Y.M.L. designed the study. J.Y.C., Y.M.L. and K.C.C. have collected and analyzed the data. J.Y.C., Y.M.L. and K.C.C. interpreted the results and drafted the manuscript. All the authors reviewed and approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.-M.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020